PharmacoEconomics

, Volume 34, Issue 8, pp 723–731 | Cite as

Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges

  • Sevan Dirmesropian
  • James G. Wood
  • C. Raina MacIntyre
  • Philippe Beutels
  • Anthony T. Newall
Current Opinion

Abstract

High-income countries are undergoing demographic transitions towards populations with substantial larger proportions of older adults. Due to the increased susceptibility of older adults to infectious diseases and their consequences, vaccination programmes are an important health intervention to help maintain healthy ageing. While much of the existing literature suggests that current vaccination programmes targeted at older adults and the elderly are likely to be cost effective in high-income countries, we argue that it is important to more fully consider some important issues and challenges. Since the majority of vaccines have been developed for children, economic evaluations of vaccination programmes have consequentially tended to focus on this age group and on how to incorporate herd-immunity effects. While programmes targeted at older adults and the elderly may also induce some herd effects, there are other important challenges to consider in these economic evaluations. For example, age and time effects in relation to vaccine efficacy and duration of immunity, as well as heterogeneity between targeted individuals in terms of risk of infection, severity of disease and response to vaccination. For some pathogens, there is also the potential for interactions with childhood programmes in the form of herd-immunity effects.

Notes

Acknowledgments

This work was supported by an Australian National Health and Medical Research Council Project grant (1081344).

Anthony T. Newall initiated the idea for article; Sevan Dirmesropian carried out the review and drafted the initial manuscript. All authors contributed to planning the structure of the article and revising the manuscript, and approved the final version.

Compliance with Ethical Standards

Potential conflicts of interest

C. Raina MacIntyre has received in-kind support and funding for investigator-driven research from GlaxoSmithKline, Pfizer, Merck, and bioCSL, and has sat on advisory boards for Merck, GlaxoSmithKline and Pfizer. Sevan Dirmesropian, James G. Wood, Philippe Beutels, and Anthony T. Newall have no potential conflicts to declare.

References

  1. 1.
    The World Bank. High income countries: OECD. Available at: http://data.worldbank.org/income-level/OEC. Accessed 14 Jan 2016.
  2. 2.
    Anderson GF, Hussey PS. Population aging: a comparison among industrialized countries. Health Aff (Millwood). 2000;19(3):191–203.CrossRefPubMedGoogle Scholar
  3. 3.
    Schoen C, et al. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff (Project Hope). 2009;28(6):w1171–83.CrossRefGoogle Scholar
  4. 4.
    Pfuntner A, Wier LM Steiner C. Costs for hospital stay in the United States, 2010. Agency for Healthcare Research and Quality (HCUP), statistical brief #146. 2013. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb146.pdf. Accessed Oct 2015.
  5. 5.
    Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien Med Wochenschr. 2006;156(5–6):130–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Centres for Disease Control and Prevention. Active Bacterial Core Surveillance (ABC’s) report: emerging infection program network, Streptococcus pneumoniae surveillance report. Atlanta: Centres for Disease Control and Prevention; 2013.Google Scholar
  8. 8.
    Insinga RP, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.Google Scholar
  10. 10.
    Esposito S, et al. Vaccine-preventable diseases: from paediatric to adult targets. Eur J Intern Med. 2014;25(3):203–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Kimman TG, et al. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006;24(22):4769–78.CrossRefPubMedGoogle Scholar
  12. 12.
    Eilers R, et al. Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatr. 2013;13(1):32.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Centers for Disease Control and Prevention (CDC). CDC vaccine price list. 1 May 2015. Available at: http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. Accessed 4 Jun 2015.
  14. 14.
    National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook 10th Edition. Canberra: Australian Government Department of Health and Ageing; 2013.Google Scholar
  15. 15.
    Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics. 2012;30(8):647–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76–82.CrossRefPubMedGoogle Scholar
  17. 17.
    International Longevity Centre UK (ILC-UK). HERON. Cost effectiveness of adult immunization strategies: report. 2013. Available at: http://www.ilcuk.org.uk/index.php/publications/publication_details/adult_vaccination_a_key_component_of_healthy_ageing. Accessed Jan 2016.
  18. 18.
    Ogilvie I, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891–904.CrossRefPubMedGoogle Scholar
  19. 19.
    Postma MJ, et al. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoeconom Outcomes Res. 2006;6(2):215–27.CrossRefGoogle Scholar
  20. 20.
    Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013;31(2):125–36.CrossRefPubMedGoogle Scholar
  21. 21.
    Newall AT, et al. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32(7):759–65.CrossRefPubMedGoogle Scholar
  22. 22.
    Barnes M, et al. Acute myocardial infarction and influenza: a meta-analysis of case–control studies. Heart. 2015;101(21):1738–47.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Grutters JPC, et al. Acknowledging patient heterogeneity in economic evaluation: a systematic literature review. Pharmacoeconomics. 2013;31(2):111–23.CrossRefPubMedGoogle Scholar
  24. 24.
    Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 2013;4:171.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Grigsby JS. The meaning of heterogeneity: an introduction. Gerontologist. 1996;36(2):145–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Lelic A, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 2012;8(12):e1003076.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Weinberger B, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078–84.CrossRefPubMedGoogle Scholar
  28. 28.
    Shapiro ED, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60.CrossRefPubMedGoogle Scholar
  29. 29.
    Castilla J, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5) (pii:20388).Google Scholar
  30. 30.
    Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMedGoogle Scholar
  31. 31.
    Ultsch B, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13(1):359.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999;108(1):1–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Panda A, et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 2009;30(7):325–33.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Olivieri F, et al. Toll like receptor signaling in “inflammaging”: microRNA as new players. Immun Ageing. 2013;10(1):11.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Schmader KE, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbid. 2011;1:28–44.CrossRefGoogle Scholar
  37. 37.
    Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1(1):CD000422.Google Scholar
  38. 38.
    Marengoni A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Constans T, Alix E, Dardaine V. Protein-calorie malnutrition in the elderly: diagnostic methods and epidemiology [in French]. Presse Med. 2000;29(39):2171–6.PubMedGoogle Scholar
  40. 40.
    Bourée P. Immunity and immunization in elderly. Pathol Biol (Paris). 2003;51(10):581–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Clegg A, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–62.CrossRefPubMedGoogle Scholar
  42. 42.
    Mitnitski A, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc. 2005;53(12):2184–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Rockwood K, et al. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc. 2006;54(6):975–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Ridda I, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine. 2009;27(10):1628–36.CrossRefPubMedGoogle Scholar
  45. 45.
    Yao X, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29(31):5015–21.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    MacIntyre CR. Elderly vaccination: the glass is half full. Sci Res. 2013;5(12A):80–5.Google Scholar
  47. 47.
    Ridda I, et al. Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded National Pneumococcal Vaccination Program in Australia. Hum Vaccin. 2007;3(3):83–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Ultsch B, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics (Epub 17 Oct 2015).Google Scholar
  49. 49.
    Sisk JE, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14.CrossRefPubMedGoogle Scholar
  51. 51.
    Lexau CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Assoc. 2005;294(16):2043–51.CrossRefGoogle Scholar
  52. 52.
    Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30(6):931–3.CrossRefPubMedGoogle Scholar
  53. 53.
    Prince MJ, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385(9967):549–62.CrossRefPubMedGoogle Scholar
  54. 54.
    Lang PO, et al. Immunosenescence: Implications for vaccination programmes in adults. Maturitas. 2011;68(4):322–30.CrossRefPubMedGoogle Scholar
  55. 55.
    Smith KJ, et al. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prevent Med. 2013;44(4):373–81.Google Scholar
  56. 56.
    Drummond MF, et al. Methods for the economic evaluation of helath care programmes. 3rd ed. Oxford: Oxford University Press; 2005.Google Scholar
  57. 57.
    Pradas R, et al. Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infect Dis. 2013;13(1):175.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Lal H, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRefPubMedGoogle Scholar
  59. 59.
    Lambrecht BN, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21(1):23–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197–208.CrossRefPubMedGoogle Scholar
  61. 61.
    Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.CrossRefPubMedGoogle Scholar
  62. 62.
    Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended adult immunization schedule-United States. MMWR. 2012;61–84.Google Scholar
  63. 63.
    Andrews RM, et al. Influenza and pneumococcal vaccine coverage among a random sample of hospitalised persons aged 65 years or more, Victoria. Commun Dis Intell Q Rep. 2005;29(3):283–8.PubMedGoogle Scholar
  64. 64.
    Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect. 2009;58(6):446–58.CrossRefPubMedGoogle Scholar
  65. 65.
    Australian Institute of Health and Welfare (AIHW). 2009 adult vaccination survey: summary results. 2011. Available at: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737418286. Accessed Jan 2016.
  66. 66.
    Eilers R, Krabbe PF, de Melker HE. Factors affecting the uptake of vaccination by the elderly in Western society. Prevent Med. 2014;69:224–34.CrossRefGoogle Scholar
  67. 67.
    Ridda I, et al. Factors associated with pneumococcal immunisation among hospitalised elderly persons: a survey of patient’s perception, attitude, and knowledge. Vaccine. 2008;26(2):234–40.CrossRefPubMedGoogle Scholar
  68. 68.
    Beutels P, et al. Seasonal influenza vaccination: prioritizing children or other target groups? Part II: cost effectiveness analysis. KCE report 204. 2013. Available at: https://kce.fgov.be/sites/default/files/page_documents/KCE_204_Seasonal_influenza_vaccination_partII.pdf. Accessed Jan 2016.
  69. 69.
    Van Hoek AJ, et al. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225–34.CrossRefPubMedGoogle Scholar
  70. 70.
    Van Den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl. 1):i89–i91.Google Scholar
  71. 71.
    Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health. 2005;29(2):136–42.CrossRefPubMedGoogle Scholar
  72. 72.
    Bognar G. Age-weighting. Econ Philos. 2008;24(02):167–89.CrossRefGoogle Scholar
  73. 73.
    Australian Bureau of Statistics (ABS). Life tables, states, territories and Australia, 2011–2013. 2014. Available at: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3302.0.55.0012011-2013?OpenDocument. Accessed 15 Jun 2015.
  74. 74.
    Stafoggia M, et al. Summer temperature-related mortality. Epidemiology. 2009;20(4):575–83.CrossRefPubMedGoogle Scholar
  75. 75.
    Rocklöv J, Forsberg B, Meister K. Winter mortality modifies the heat-mortality association the following summer. Eur Respir J. 2009;33(2):245–51.CrossRefPubMedGoogle Scholar
  76. 76.
    Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine. 2015;33(32):3788–94.CrossRefPubMedGoogle Scholar
  77. 77.
    Brouwer WBF, et al. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ. 2005;331(7514):446–8.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2011.Google Scholar
  79. 79.
    Mossong J, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):0381–91.CrossRefGoogle Scholar
  80. 80.
    Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105(12):1776–83.CrossRefPubMedGoogle Scholar
  81. 81.
    Chiu C, Dey A, Wang H. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell. 2010;34(Suppl):S1–167.CrossRefGoogle Scholar
  82. 82.
    Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(Suppl. 1):S31–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Sevan Dirmesropian
    • 1
  • James G. Wood
    • 1
  • C. Raina MacIntyre
    • 1
  • Philippe Beutels
    • 1
    • 2
  • Anthony T. Newall
    • 1
  1. 1.Samuels Building, School of Public Health and Community MedicineUNSW AustraliaSydneyAustralia
  2. 2.Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID) and Centre for the Evaluation of Vaccination (CEV), Vaccine and Infectious Disease InstituteUniversity of AntwerpAntwerpBelgium

Personalised recommendations